About Us

Rich Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of its lead product, RP-323, (12-O- tetradecanoyl- phorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in these and possibly other indications is the result of the Prof. Richard Chang.  He has conducted research on TPA for many years and have become an expert in the characteristics of this molecule. Their findings form the scientific basis for the clinical use of TPA. » Read more about us

Latest News

July 23

Rich Pharmaceuticals Hires Contract Research Organization to File NDA and Identify Clinical Trial Site(s) for Lead Compound View Release

May 6

Rich Pharmaceuticals Appoints Dr. Chieanchuang Kalayanamitr to Medical Advisory Board View Release

April 17

Rich Pharmaceuticals Appoints Professor Richard L. Chang to Medical Advisory Board View Release

» Read Latest News